Share price movements

On April 30, Pfizer (PFE) reported first-quarter results. The company reported revenues of $13.12 billion in the first quarter, a YoY rise of 2% on a reported basis and 5% on an operational basis. According to the company’s first-quarter earnings conference call, this performance was driven by 8% YoY volume growth but partly offset by a 3% drop in pricing.

In the first quarter, Pfizer reported GAAP EPS of $0.68, a YoY rise of 15.25%. The company reported non-GAAP EPS of $0.85, a YoY rise of 10.39% on a reported basis.

What Are Analysts Recommending for PFE after Q1 Results?

Sign up for Bagels & Stox, our witty take on the top market and investment news, straight to your inbox! Whether you’re a serious investor or just want to be informed, Bagels & Stox will be your favorite email.

Pfizer surpassed consensus revenue estimates by $110 million and the consensus EPS estimate by $0.10 in the first quarter. After the results, Pfizer closed at $40.61 on April 30, 2.58% higher than the previous close, 18.16% higher than the 52-week low of $34.37, and 12.61% lower than the 52-week high of $46.47. The company’s market capitalization was $235.17 billion and PE, forward PE, PS (price-to-sales), PB (price-to-book), and PC (price-to-cash) ratios were 23.62x, 13.26x, 4.38x, 3.71x, and 12.49x, respectively. On May 1, the stock closed at $40.77, 0.39% higher than the previous close.

On April 30, Pfizer’s 14-day RSI (relative strength index) was 44.98. The number of outstanding shares for the company is 5.79 billion, while the short float ratio is 2.77%.

Analysts’ recommendations and target price

Wall Street analysts expect upside potential of 8.52% for Pfizer based on the company’s closing price on April 30. Analysts have changed the company’s 12-month consensus target price from $44.54 in January to $44.14 in February to $44.36 in March and then to $44.07 in April.

Out of 15 analysts covering Pfizer, two analysts recommend a  “strong buy,” five recommend a “buy,” seven recommend a “hold,” and one recommends a “strong sell.” The consensus recommendation for the company is “hold.”

Latest articles

This year, Pfizer (PFE) stock has fallen 0.34% and Bristol-Myers Squibb (BMY) stock has fallen 6.48%. Both companies are focused on strengthening their position in the high-growth oncology and immunology markets. Let's take a closer look at each.

Walt Disney’s (DIS) latest movie, Toy Story 4, has reportedly broken records in the opening weekend with $118 million in sales. However, the opening weekend collection was behind analysts’ expectations of at least $150 million in the first weekend.

24 Jun

Will Home Depot’s Upward Momentum to Continue?

WRITTEN BY Rajiv Nanjapla

As of June 21, Home Depot (HD) was trading at $209.39, which implies a rise of 9.7% since the announcement of its first-quarter earnings on May 21. Also, the company was trading at a premium of 32.4% from its 52-week low of $158.09 and a discount of 2.8% from its 52-week high of $215.43.

On June 21, Aurora Cannabis (ACB) made an announcement that indicated that it will move towards higher margin vape products. In addition, the company also believes concentrates and edibles will command higher margins. In anticipation of this development, the company announced the expansion of its facility to capitalize on growth related to these segments.

Shares of Mondelēz International (MDLZ) are scaling new heights thanks to its stellar gains so far this year. Mondelēz stock is up 38.0% on a YTD (year-to-date) basis, and it closed at $55.25—just a shade lower than its 52-week high of $55.71—on June 21.

24 Jun

How Long Will Facebook's Libra Fuel Bitcoin Rally?

WRITTEN BY Mayur Sontakke, CFA, FRM

Ever since the news about Facebook’s (FB) cryptocurrency project broke, Bitcoin has rallied on the hope that Facebook’s entry in the space will help make cryptocurrencies mainstream. Facebook’s cryptocurrency will be called Libra and will be governed by an association with 28 founding members across industries.